Immune markers correlate with clinical outcomes following nucleos(t)ide analogue withdrawal in chronic hepatitis B
Immune Markers May Predict Outcomes After Hepatitis B Treatment
This mini review synthesizes immune correlates of outcome after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B. Bene…
New research identifies specific immune markers that may help predict how patients respond when stopping nucleoside analogue medications for…
Gut-brain axis dysregulation links Crohn's disease activity with heterogeneous mood improvements from emerging therapies
Newer gut brain therapies show promise for Crohn's disease depression
This narrative review explores the gut-brain axis as a mechanism for depression in patients with Crohn's disease. The authors synthesize evi…
Living with Crohn's disease and depression is a heavy burden. New research explores how targeting the gut brain axis could help manage both …
Skin lesions typically precede spinal arthritis in patients with follicular occlusion triad and spondyloarthritis
Skin issues may signal upcoming spinal arthritis in some patients
This case report and literature review examines the clinical patterns of peripheral and axial spondyloarthritis in patients with follicular …
New data shows that skin lesions often appear years before spinal arthritis begins in patients with specific inflammatory conditions.
Precision glucocorticoid dosing remains investigational; genetic markers not yet clinically actionable
New research explores personalized dosing for steroid medications
This guideline review outlines a precision medicine framework for glucocorticoid therapy in immune-mediated diseases, incorporating pharmaco…
Doctors are looking at how genetic testing and biomarkers can help tailor steroid doses for people with inflammatory diseases.
Infliximab treatment in pediatric IBD is associated with specific microbial shifts rather than uniform diversity recovery
Infliximab Treatment Linked to Specific Gut Bacteria in Children
This systematic review of 242 pediatric patients with inflammatory bowel disease examines the impact of infliximab on the microbiome. The au…
New research shows that children with inflammatory bowel disease may have specific gut bacteria changes when treated with the medication inf…
Pediatric GERD and proton pump inhibitor exposure are associated with reduced microbial diversity
Proton Pump Inhibitors Linked to Changes in Childrens Gut Health
This systematic review of 31 studies examines the impact of gastroesophageal reflux disease (GERD) and proton pump inhibitor (PPI) use on th…
New research suggests that proton pump inhibitors for childhood reflux may lead to less diverse gut bacteria and other changes in the microb…
Immune checkpoint inhibitors in rectal cancer: balancing anti-tumor effects against ICI-associated colorectal injury
Immune drugs for rectal cancer can cause intestinal damage
This systematic review examines immune checkpoint inhibitors (ICIs) in rectal cancer, highlighting robust anti-tumor effects in dMMR/MSI-H t…
New research explores how specific proteins in the gut help manage side effects from immune checkpoint inhibitors used to treat rectal cance…
Traditional Chinese Medicine potentially influences gastrointestinal motility and gut microbiota in Irritable Bowel Syndrome
Traditional Chinese Medicine may help manage Irritable Bowel Syndrome
This narrative review explores the role of Traditional Chinese Medicine (TCM) in managing Irritable Bowel Syndrome by examining mechanisms l…
New research explores how Traditional Chinese Medicine could influence gut health and brain signaling for those with Irritable Bowel Syndrom…
Gut microbiota alpha diversity increases during the first year of life in infants and toddlers
Gut bacteria diversity in infants peaks around 12 months
This systematic review and meta-analysis of 95 studies synthesized data on gut microbiota development from infancy to toddlerhood. The analy…
New data shows that the variety of gut bacteria in babies and toddlers increases significantly during their first year of life.
FABP2 serves as a sensitive biomarker of intestinal mucosal injury in inflammatory bowel disease
FABP2 Protein May Help Identify Inflammatory Bowel Disease Damage
This systematic review examines the role of fatty acid-binding protein 2 (FABP2) in inflammatory bowel disease. The authors conclude that FA…
A new protein called FABP2 shows promise as a sensitive marker for identifying intestinal damage in people with inflammatory bowel disease.
FDA Approves Iqirvo (elafibranor) for Primary Biliary Cholangitis
FDA approves new drug Iqirvo for a rare liver disease.
The FDA has approved Iqirvo (elafibranor) for primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults wi…
The FDA has approved Iqirvo (elafibranor) for adults with primary biliary cholangitis (PBC), a chronic liver disease. It is used when standa…
ALPPS yields fastest liver growth but worse 1-year DFS than PVE in meta-analysis
ALPPS surgery shows faster liver growth for tumor removal
This meta-analysis of 24 retrospective cohort studies (1263 patients) compared ALPPS, PVE, and LVD for liver hypertrophy before major hepate…
A new analysis of over 1,200 patients reveals that the ALPPS technique leads to faster liver growth and higher completion rates for major su…